ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
19.146,17
0,76%
S&P 500
5.948,71
0,53%
Dow Jones
43.870,35
1,06%
Euro vs US Dollar
1,04725
-0,70%
Bitcoin
98.639,04
4,54%
Pepperstone
Advertisement
Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. Europa
  5. EU
  6. Argen X SE (ARGX)

  7. Argen X SE (ARGX) News

ARGX

Argen X (ARGX)

Argen X SE
Von:
Sortieren nach:
 Showing the most relevant articles for your search:EU:ARGX
DatumZeitQuelleÜberschriftSymbolFirma
20/11/202407h00GlobeNewswire Inc.argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory MyopathiesEU:ARGXArgen X SE
11/11/202413h30GlobeNewswire Inc.argenx and Zai Lab Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy in ChinaEU:ARGXArgen X SE
05/11/202407h00GlobeNewswire Inc.argenx to Participate at Upcoming Investor ConferencesEU:ARGXArgen X SE
31/10/202407h00GlobeNewswire Inc.argenx Reports Third Quarter 2024 Financial Results and Provides Business UpdateEU:ARGXArgen X SE
24/10/202407h00GlobeNewswire Inc.argenx to Report Third Quarter 2024 Financial Results and Business Update on October 31, 2024EU:ARGXArgen X SE
15/10/202407h00GlobeNewswire Inc.argenx Highlights Data Showing Patient Impact Across Multiple Immunology Programs at 2024 American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting and Myasthenia Gravis Foundation of America Scientific SessionsEU:ARGXArgen X SE
19/09/202407h00GlobeNewswire Inc.argenx Announces Publication in The Lancet Neurology of Pivotal ADHERE Study Data in Chronic Inflammatory Demyelinating PolyneuropathyEU:ARGXArgen X SE
28/08/202407h00GlobeNewswire Inc.argenx to Present at Upcoming Investor ConferencesEU:ARGXArgen X SE
25/07/202407h00GlobeNewswire Inc.argenx Reports Half Year 2024 Financial Results and Provides Second Quarter Business UpdateEU:ARGXArgen X SE
18/07/202407h00GlobeNewswire Inc.argenx to Report Half Year 2024 Financial Results and Second Quarter Business Update on July 25, 2024EU:ARGXArgen X SE
16/07/202406h30GlobeNewswire Inc.argenx and Zai Lab Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in ChinaEU:ARGXArgen X SE
25/06/202422h30GlobeNewswire Inc.argenx Highlights Breadth of Autoimmune Pipeline with New Multifocal Motor Neuropathy Data at 2024 Peripheral Nerve Society Annual MeetingEU:ARGXArgen X SE
21/06/202422h50GlobeNewswire Inc.argenx Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating PolyneuropathyEU:ARGXArgen X SE
17/06/202407h00GlobeNewswire Inc.argenx to unveil its ‘Vision 2030: Taking Breakthrough Science to 50,000 Patients’ during its Upcoming R&D Day on July 16, 2024EU:ARGXArgen X SE
04/06/202407h00GlobeNewswire Inc.argenx to Present at Goldman Sachs 45th Annual Global Healthcare ConferenceEU:ARGXArgen X SE
09/05/202407h00GlobeNewswire Inc.argenx Reports First Quarter 2024 Financial Results and Provides Business UpdateEU:ARGXArgen X SE
07/05/202423h30GlobeNewswire Inc.argenx announces results of Annual General Meeting of ShareholdersEU:ARGXArgen X SE
07/05/202407h00GlobeNewswire Inc.argenx to Present at BofA Securities 2024 Health Care ConferenceEU:ARGXArgen X SE
02/05/202407h00GlobeNewswire Inc.argenx to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024EU:ARGXArgen X SE
16/04/202407h00GlobeNewswire Inc.argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune DiseaseEU:ARGXArgen X SE
27/03/202407h00GlobeNewswire Inc.argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s DiseaseEU:ARGXArgen X SE
26/03/202421h00GlobeNewswire Inc.argenx Announces Annual General Meeting of Shareholders on May 7, 2024EU:ARGXArgen X SE
26/03/202407h00GlobeNewswire Inc.argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune ThrombocytopeniaEU:ARGXArgen X SE
07/03/202422h01GlobeNewswire Inc.argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of Neurology 2024 Annual MeetingEU:ARGXArgen X SE
29/02/202407h00GlobeNewswire Inc.argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business UpdateEU:ARGXArgen X SE
26/02/202407h00GlobeNewswire Inc.argenx to Present at Upcoming Investor ConferencesEU:ARGXArgen X SE
22/02/202407h00GlobeNewswire Inc.argenx to Report Full Year 2023 Financial Results and Fourth Quarter Business Update on February 29, 2024EU:ARGXArgen X SE
20/02/202407h00GlobeNewswire Inc.argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART Hytrulo in Chronic Inflammatory Demyelinating PolyneuropathyEU:ARGXArgen X SE
18/01/202407h00GlobeNewswire Inc.argenx Announces Approval of VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Japan for Generalized Myasthenia GravisEU:ARGXArgen X SE
08/01/202407h00GlobeNewswire Inc.argenx Highlights 2024 Strategic PrioritiesEU:ARGXArgen X SE
 Showing the most relevant articles for your search:EU:ARGX

Kürzlich von Ihnen besucht

COIN
ADAUSD
Cardano
COIN
DOGEUSD
Dogecoin
COIN
BTCUSD
Bitcoin
USOTC
RHHBY
Roche (QX)
DBI
DAX
DAX
NYSE
KO
Coca Cola
AMEX
SPY
SPDR S&P 500
NYSE
MCD
McDonalds
TG
ALV
Allianz
CCOM
SILVER
SILVER
DBI
TDXP
Tec DAX
PM
XAUUSD
Gold vs US Dollar
FX
EURJPY
Euro vs Yen
CCOM
US100
US Tech 100
AMEX
XLF
Financial Select Sector
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten